A continuous increase in follicular lymphoma has been observed in Taiwan, Japan, and South Korea over the last few decades. This study aimed to evaluate the difference in incidence trends of follicular lymphoma in Taiwan, Japan, and South Korea between 2001 and 2019. The data for the Taiwanese populations was obtained from the Taiwan Cancer Registry Database, and those for the Japanese and Korean population were retrieved from the Japan National Cancer Registry and some additional reports, both of which included population-based cancer registry data, from Japan and Korea. Follicular lymphoma accounted for 4231 cases from 2002–2019 in Taiwan, 3744 cases from 2001–2008 and 49,731 cases from 2014–2019 in Japan; and 1365 cases from 2001–2012 and 1244 cases from 2011–2016 in South Korea. The annual percentage change for each time period was 3.49% (95% confidence interval: 2.75–4.24%) in Taiwan, 12.66% (95% confidence interval [CI]: 9.59–15.81%) and 4.95% (95% CI: 2.14–7.84%) in Japan, and 5.72% (95% CI: 2.79–8.73%) and 7.93% (95% CI: −1.63–18.42%) in South Korea. Our study confirms that the increasing trends of follicular lymphoma incidence in Taiwan and Japan have been remarkable in recent years, especially the rapid increase in Japan between 2014 and 2019; however, there was no significant in-crease from 2011 to 2015 in South Korea.
Some studies showed that when distant metastasis or locally advanced tumors were observed, the participation of 2 or more operating surgeons (combined surgery) in the operation could improve the prognosis of patients. The multispecialty operative team would perform combined surgery in colon cancer patients with some complications since 2015.The goal of this study is to confirm performing combined surgery would improve the outcomes of colon cancer patients.A retrospective observational study was conducted, which involved all colon cancer patients between November 2015 and December 2019 at one would-be medical center. Patients were divided into 3 cohorts: those with complicated cases and had combined surgery (C_2S), those with complicated cases and had surgery performed by a single surgeon (C_1S), and those with uncomplicated cases and had surgery performed by a single surgeon (NC_1S). Overall survival and disease-free survival were compared among the 3 groups.A total of 296 colon cancer patients during the study period. Among them, 35 were C_2S, 87 were C_1S, and 174 were NC_1S. Patients in the NC_1S group had significantly higher 12-, 24-, and 36-month OS rates compared to those in the C_1S group (P < .01). In contrast, there was no significant difference in overall survival among patients in the NC_1S and C_2S group (P =.15).The quality of surgery must be impact the prognosis, especially in the individual who was complicated case, the survival in patients who had surgery performed by multispecialty operative team would be improved.Abbreviations: C_1S = patients with complicated cases and had surgery performed by a single surgeon, C_2S = patients with complicated cases and had combined surgery, CRC = colorectal cancer, CI = confidence interval, CT = computed tomography, DFS = disease-free survival, ELN = examined lymph node, HR = hazard ratio, LOS = length of stay, mCRC = metastatic colorectal cancer, NC_1S = patients with uncomplicated cases and had surgery performed by a single surgeon, OS = overall survival, R0 = resection for cure, SD = standard deviation, TCRD = Taiwan Cancer Registry Database.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.